Cresilon

Cresilon is a Brooklyn-based biotechnology company that develops, manufactures, and markets hemostatic medical devices utilizing the company’s proprietary hydrogel technology. Their plant-based technology has revolutionized the current standard by stopping bleeding in seconds, without the need for manual pressure. Cresilon’s product lines target veterinary, human trauma, and human surgical applications.

Cresilon has achieved significant success in the veterinary market with VETIGEL, a hemostatic gel for veterinary use only. The company is currently expanding into the human health market with their product TRAUMAGEL, a hemostatic gel for temporary external use to control moderate to severe bleeding. They are also engaged in research and development for the treatment of traumatic brain injuries.

Cresilon is a Brooklyn-based biotechnology company focused on developing and manufacturing innovative hemostatic medical devices that utilize the company's proprietary hydrogel technology. Their mission is to save lives by revolutionizing the standard of care in wound treatment and hemostasis with their plant-based hemostatic gel, which stops bleeding in seconds without the need for manual pressure. Cresilon's current and future product lines target veterinary, human trauma, and human surgical applications.

Cresilon's company culture is driven by a strong mission to save lives. The company prioritizes innovation and fosters a collaborative environment, evident in its commitment to developing and manufacturing its hemostatic gel technology. This focus on innovation is reflected in Cresilon's team of passionate and experienced individuals who are dedicated to improving the standard of care in wound treatment. Their culture is one of continuous learning and improvement, driven by a shared belief in the power of their plant-based technology.